Article Versions Notes

Asiri YI, Pichaivel M, Parameshwaran SP, Venkatesan K, Alqahtani S, Alqahtani T, Ahmed R, Elfadil H, Elodemi M, Genena S, et al. Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy. Pharmaceuticals. 2025; 18(5):762. https://doi.org/10.3390/ph18050762

Asiri, Yahya I., Manimekalai Pichaivel, Selva Prasanthi Parameshwaran, Krishnaraju Venkatesan, Saud Alqahtani, Taha Alqahtani, Rehab Ahmed, Hassabelrasoul Elfadil, Mahmoud Elodemi, Shaimaa Genena, and et al. 2025. "Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy" Pharmaceuticals 18, no. 5: 762. https://doi.org/10.3390/ph18050762

Asiri, Y. I., Pichaivel, M., Parameshwaran, S. P., Venkatesan, K., Alqahtani, S., Alqahtani, T., Ahmed, R., Elfadil, H., Elodemi, M., Genena, S., Sivadasan, D., & Paulsamy, P. (2025). Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy. Pharmaceuticals, 18(5), 762. https://doi.org/10.3390/ph18050762